Evidence map›Paper›PMID 40321290›Full record

ArticlemedRxiv : the preprint server for health sciences2025

Neutralizing Antibody Responses After mRNA COVID-19 Booster Vaccination are Unaffected by Parasitemia in a Malaria-Endemic Setting.

Taraz Samandari, Millicent Achola, Jack N Hutter, Grace Mboya, Walter Otieno, Jia Jin Kee, Yunda Huang, John J Aponte, Christian F Ockenhouse, Cynthia K Lee and 11 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors.

Taraz SamandariCOVID-19 Prevention Network, Seattle, USA.ORCID 0000-0003-4830-6108
Millicent AcholaU.S. Army Medical Research Directorate-Africa, Kisumu, Kenya.
Jack N HutterU.S. Army Medical Research Directorate-Africa, Kisumu, Kenya.
Grace MboyaKenya Medical Research Institute, Centre for Global Health Research, Kisumu, Kenya.
Walter OtienoU.S. Army Medical Research Directorate-Africa, Kisumu, Kenya.
Jia Jin KeeVaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, USA.
Yunda HuangVaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, USA.
John J ApontePATH Center for Vaccine Innovation and Access, Geneva, Switzerland.
Christian F OckenhousePATH Center for Vaccine Innovation and Access, Washington, District of Columbia, USA.
Cynthia K LeePATH Center for Vaccine Innovation and Access, Washington, District of Columbia, USA.
Laura PolakowskiNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, USA.
Margaret YacovoneNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, USA.
Asa TapleyVaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, USA.
Sufia DadabhaiJohns Hopkins Bloomberg School of Public Health, Blantyre, Malawi.
Nonhlanhla N MkhizeNational Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa.
Haajira KaldineNational Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa.
Sinethemba BhebheNational Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa.
Penny L MooreNational Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa.
John HuralVaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, USA.
Nigel GarrettDesmond Tutu HIV Centre, University of Cape Town, South Africa.
James G KublinVaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, USA.

Funding

LOC: HIV Vaccine Trials NetworkUM1AI068614 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Dan H. Barouch, Lawrence Corey · 2011 to 2026
$1175.6M
LC: HIV Vaccine Trials NetworkUM1AI068618 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Margaret Juliana McElrath · 2011 to 2026
$483.6M
SDMC: HIV Vaccine Trials NetworkUM1AI068635 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Peter B. Gilbert, Yunda Huang · 2011 to 2026
$385.9M
Leadership Group for a Global HIV Vaccine Clinical Trials NetworkU01AI068614 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI COREY, LAWRENCE · 2006 to 2010
$181.5M
Leadership for HIV/AIDS Clinical Trials Networks; HIV Vaccine Trials NetworkU01AI068635 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI SELF, STEVEN G. · 2006 to 2010
$53.8M
HOST DEFENSE TRAINING IN ALLERGY AND INFECTIOUS DISEASEST32AI007044 · NIAID · UNIVERSITY OF WASHINGTON · PI DAVID Neal FREDRICKS · 1985 to 2026
$14.6M
Gates Foundation INV-007217NIAID NIH HHS T32 AI007044NIAID NIH HHS U01 AI068614NIAID NIH HHS U01 AI068635NIAID NIH HHS UM1 AI068614NIAID NIH HHS UM1 AI068618NIAID NIH HHS UM1 AI068635
6 · The paper itself

Abstract

Subclinical malaria may reduce the immunogenicity of mRNA vaccines. We evaluated neutralizing antibody responses in adults with (n=87) and without (n=221) PCR-confirmed

Indexed as

boosterHIVimmunogenicitymalariamRNA vaccineneutralizing antibodySARS-CoV-2

Identifiers

PMID40321290
PMCPMC12047954

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.